Nouns Cola now has a fundable brief, not just a flavor mood.
The useful judgment call is simple: raise against the classic cola pilot first, and keep the adaptogen lane as a gated R&D branch. That makes the first capital story easier to explain to sponsors, collaborators, and anyone sane enough to ask what actually ships first.
The brief lays out the recommendation directly. Formula 01 stays the launch SKU. Formula 02 is the calmer functional branch, with ashwagandha as the most evidence-backed adaptogen candidate but still behind safety, formulation, and labeling review. Rhodiola and ginseng remain later experiments, not the spine of the opening raise.
The capital split follows the same logic. Most of the money sits under the pilot run: formula work, co-packer deposit, inventory, freight, compliance, and launch media. A smaller reserve funds adaptogen R&D so the next SKU can be explored without turning the first one into a regulatory dare.
That is the cleaner pitch: fund the beverage everyone understands, publish the gates in public, and earn the functional extension instead of hiding uncertainty inside the can.